Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 3
1(25.0%)
Phase 1
1(25.0%)
4Total
Phase 2(2)
Phase 3(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07189169Phase 3Recruiting

QA108 Phase III Study in Subjects With Intermediate AMD

Role: lead

NCT05536752Phase 2Completed

QA102 Phase II Study in Subjects With Dry AMD

Role: lead

NCT05562219Phase 2Completed

QA108 Phase II Study in Subjects With Intermediate Age-Related Macular Degeneration

Role: lead

NCT04894071Phase 1Completed

QA102 Phase 1 Study in Healthy Young and Older Adult Subjects

Role: lead

All 4 trials loaded